Resource Summary Report

Generated by dkNET on Sep 1, 2026

Daoy

RRID:CVCL_1167
Type: Cell Line

Proper Citation

RRID:CVCL_1167

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1167

Proper Citation: RRID:CVCL_1167

Description: Cell line Daoy is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Medulloblastoma, SHH-activated, TP53-mutant

Defining Citation: PMID:1822845, PMID:2993532, PMID:12973738, PMID:18773455, PMID:20164919, PMID:20847082, PMID:22343310, PMID:22460905, PMID:22723427, PMID:24297863, PMID:25877200, PMID:27397505, PMID:27498314, PMID:27812533, PMID:29900115, PMID:30894373, PMID:31068700, PMID:31346954, PMID:31963405, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Daoy

Synonyms: DAOY, D324 Med, D-324 Med, D324 MED, D-324MED, D324

Cross References: BTO:BTO_0004328, CLO:CLO_0002699, EFO:EFO_0005698, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-186, BCRJ:0325, BioGRID_ORCS_Cell_line:687, BioSample:SAMN03470909, BioSample:SAMN10988097, cancercelllines:CVCL_1167, CCRID:1101HUM-PUMC000218, CCRID:3101HUMSCSP509, Cell_Model_Passport:SIDM00887, ChEMBL-Cells:CHEMBL3308510, ChEMBL-

Targets:CHEMBL612519, CLS:305053, Cosmic:687773, Cosmic:906833, Cosmic:923654, Cosmic:973262, Cosmic:974281, Cosmic:975027, Cosmic:1404441, Cosmic:1995383, Cosmic:2362649, Cosmic:2731177, Cosmic-CLP:906833, DepMap:ACH-000211, EGA:EGAS00001000978, ENCODE:ENCBS055ILX, ENCODE:ENCBS812KQP, GDSC:906833, GEO:GSM482332, GEO:GSM886972, GEO:GSM888041, GEO:GSM919361, GEO:GSM1669725, GEO:GSM1938719, IARC_TP53:480, KCB:KCB 2010203YJ, LiGeA:CCLE_339, LINCS_LDP:LCL-1576, Lonza:1438, NCBI_Iran:C519, PharmacoDB:Daoy_282_2019, PRIDE:PXD030304, Progenetix:CVCL_1167, PubChem_Cell_line:CVCL_1167, Wikidata:Q29511023

ID: CVCL_1167

Record Creation Time: 20220427T215744+0000

Record Last Update: 20260829T232429+0000

Ratings and Alerts

No rating or validation information has been found for Daoy.

No alerts have been found for Daoy.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Kubon N, et al. (2026) Detection of structural DNA variants in medulloblastomas using optical genome mapping. Acta neuropathologica communications, 14(1).

Tuerxun K, et al. (2026) Exploring the prognostic molecular mechanisms of medulloblastoma through methylation-transcriptome integration. SAGE open medicine, 14, 20503121251386139.

Wu YS, et al. (2026) 7,7''-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma. Journal of translational medicine, 24(1).

Wang Y, et al. (2026) GPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses. Journal of biomedical research, 40(3), 228.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. Molecular cancer therapeutics, 25(1), 156.

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. Cancers, 18(3).

Gurbuz M, et al. (2026) The MALAT1-EZH2 axis regulates PRC2 activity and promotes the mesenchymal phenotype in pediatric atypical teratoid/rhabdoid tumors. Journal of neuro-oncology, 177(2).

Gou P, et al. (2025) The dual HDAC/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma. Cell death discovery, 11(1), 172.

Kr??ger C, et al. (2025) Epidermal growth factor receptor specific immunotherapy for SHH medulloblastoma tested in an in vitro blood-brain barrier-model. Cancer treatment and research communications, 44, 100950.

Teisseire M, et al. (2025) De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma. Cancer research, 85(10), 1857.

Dhar SS, et al. (2025) Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS. Cell reports, 44(5), 115619.

Chen M, et al. (2025) Profiling tumour-infiltrating immune cells in a large paediatric medulloblastoma cohort: a retrospective analysis. EBioMedicine, 122, 106043.

Merk DJ, et al. (2024) Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. Genome biology, 25(1), 301.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. Molecular cell, 84(2), 261.

Katsushima K, et al. (2024) A therapeutically targetable positive feedback loop between lnc-HLX-2-7, HLX, and MYC that promotes group 3 medulloblastoma. Cell reports, 43(3), 113938.

Su J, et al. (2024) Identification and validation of a metabolism-related gene signature for predicting the prognosis of paediatric medulloblastoma. Scientific reports, 14(1), 7540.

Romagnoli R, et al. (2023) Design, synthesis, and biological investigation of selective human carbonic anhydrase II, IX, and XII inhibitors using 7-aryl/heteroaryl triazolopyrimidines bearing a sulfanilamide scaffold. Journal of enzyme inhibition and medicinal chemistry, 38(1), 2270180.

Denisova OV, et al. (2023) PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells. Molecular oncology, 17(9), 1803.

Faria Assoni A, et al. (2023) Neurodegeneration-associated protein VAPB regulates proliferation in medulloblastoma. Scientific reports, 13(1), 19481.

Kim J, et al. (2023) Evolutionarily conserved regulators of tau identify targets for new therapies. Neuron, 111(6), 824.